Search

Your search keyword '"Cell Line, Tumor enzymology"' showing total 173 results

Search Constraints

Start Over You searched for: Descriptor "Cell Line, Tumor enzymology" Remove constraint Descriptor: "Cell Line, Tumor enzymology"
173 results on '"Cell Line, Tumor enzymology"'

Search Results

1. Characterization of methylthioadenosin phosphorylase (MTAP) expression in colorectal cancer.

2. Mechanism of noradrenaline-induced α1-adrenoceptor mediated regulation of Na-K ATPase subunit expression in Neuro-2a cells.

3. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.

4. Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions.

5. Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.

6. Expression of sulfotransferase SULT1A1 in cancer cells predicts susceptibility to the novel anticancer agent NSC-743380.

7. A novel cell line derived from pleomorphic adenoma expresses MMP2, MMP9, TIMP1, TIMP2, and shows numeric chromosomal anomalies.

8. Generation and characterization of a JAK2V617F-containing erythroleukemia cell line.

9. Phospholipid-modified upconversion nanoprobe for ratiometric fluorescence detection and imaging of phospholipase D in cell lysate and in living cells.

10. A furanyl acryl conjugated coumarin as an efficient inhibitor and a highly selective off-on fluorescent probe for covalent labelling of thioredoxin reductase.

11. Inverse correlation between Thr-669 and constitutive tyrosine phosphorylation in the asymmetric epidermal growth factor receptor dimer conformation.

12. Metabolic characterization of cell systems used in in vitro toxicology testing: lung cell system BEAS-2B as a working example.

13. Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

14. A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.

15. Effects of azacitidine on matrix metalloproteinase-9 in acute myeloid leukemia and myelodysplasia.

16. [Effect of Mn(II) on the error-prone DNA polymerase iota activity in extracts from human normal and tumor cells].

17. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.

18. Nonradioactive in vitro assays for histone deacetylases.

19. Interleukin-1 beta and transforming growth factor-beta 3 cooperate to activate matrix metalloproteinase expression and invasiveness in A549 lung adenocarcinoma cells.

20. Celecoxib inhibits invasion and metastasis via a cyclooxygenase 2-independent mechanism in an in vitro model of Ewing sarcoma.

21. [Botulinum toxin type-A toxin activity on prostate cancer cell lines].

22. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.

23. [Establishment of the cell line that human lung adenocarcinoma can stably express luciferase which is absent of nm23-H1 expression and detecting its luminescence
in vitro and in vivo].

24. The tumour suppressor FOXO3 is a key regulator of mantle cell lymphoma proliferation and survival.

25. Establishment and detailed functional and molecular genetic characterisation of a novel sacral chordoma cell line, MUG-Chor1.

26. IL-1β down-regulates ADAMTS-13 mRNA expression in cells of the central nervous system.

27. Characterization of hydrogen sulfide and its synthases, cystathionine β-synthase and cystathionine γ-lyase, in human prostatic tissue and cells.

28. Isolation and characterization of a murine P388 leukemia line resistant to thiarabine.

29. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.

30. Isolation and characterization of a murine P388 leukemia line resistant to clofarabine.

31. Glutathione peroxidase isoenzymes in human tumor cell lines.

32. Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells.

33. Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors.

34. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.

35. Low expression of aldehyde dehydrogenase 1A1 (ALDH1A1) is a prognostic marker for poor survival in pancreatic cancer.

36. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.

37. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells.

38. Effect of a chloride channel inhibitor, 5-nitro-2-(3-phenylpropylamino)-benzoate, on ovarian cancer cell migration.

39. Suppression of matrix metalloproteinase-9 expression by RNA interference inhibits SGC7901 gastric adenocarcinoma cell growth and invasion in vitro and in vivo.

40. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.

41. Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model.

42. Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.

43. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib.

44. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology.

45. Novel angiogenesis inhibitory activity in cinnamon extract blocks VEGFR2 kinase and downstream signaling.

46. BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.

47. A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate.

48. Breast cancer invasion is mediated by beta-N-acetylglucosaminidase (beta-NAG) and associated with a dysregulation in the secretory pathway of cancer cells.

49. The prolyl-hydroxylase EGLN3 and not EGLN1 is inactivated by methylation in plasma cell neoplasia.

50. Activation of SHIP via a small molecule agonist kills multiple myeloma cells.

Catalog

Books, media, physical & digital resources